MedTrace Logo

A Study to Compare PK and Safety of CKD-381 and D026 in Healthy Male Subjects

NCT03444402 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2018-05-24

No results posted yet for this study

Summary

A Study to compare pharmacokinetics and safety of CKD-381 and D026 in healthy male subjects

Conditions

  • GERD

Interventions

DRUG

CKD-381(formulation I)

1 tablet administered before the breakfast during 7 days

DRUG

CKD-381(formulation II)

1 tablet administered before the breakfast during 7 days

DRUG

D026(Nexium 40mg)

1 tablet administered before the breakfast during 7 days

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Kyung Sang Yu, M.D · Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-02
Primary Completion
2018-05-04
Completion
2018-05-04

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03444402 on ClinicalTrials.gov